Day: March 1, 2021

CAPITALISED TERMS DEFINED IN THE CIRCULAR DATED 11 JANUARY 2021 HAVE THE SAME MEANING WHEN USED IN THIS ANNOUNCEMENT, UNLESS OTHERWISE DEFINED IN THIS ANNOUNCEMENT.1 March 2021                                                                              LEI: 213800ZBKL9BHSL2K459NOMINAL SHARE VALUE REDUCTION BECOMES EFFECTIVEOSB GROUP PLC (“OSB Group” or the “Company”) is pleased to announce that, following the sanction by the High Court of Justice in England and Wales (the “Court”) of the reduction of the nominal value of OSB Group Shares from three hundred and four (304) pence each to one (1) penny each (the “Capital Reduction”) on 23 February 2021, the order of the Court confirming the Capital Reduction and, a statement of capital approved by the Court, were registered with the Registrar of Companies on 26 February 2021. Accordingly,...

TORONTO, March 01, 2021 (GLOBE NEWSWIRE) — Cerro Grande Mining Corporation (the “Company” or “CEG”) (CSE:CEG) reported its unaudited results for the first fiscal quarter ended December 31, 2020 compared to the same quarter in 2019. These financial statements and MD&A have been filed on SEDAR and the Company refers the reader to those materials for additional information.Cerro Grande Mining Corporation is an exploration and development company with properties and activities currently focused in Chile.Cautionary Statement on Forward-looking Information:This news release contains “forward-looking information”, which may include, but is not limited to, statements with respect to the future financial or operating performance of CEG. Often, but not always, forward-looking statements can be identified by the use of words...

Nordecon AS group company Kaurits OÜ concluded an annex to the contract with GRK Infra AS for additional earthworks at Võõbu–Mäo road construction project (main contract announcement). The value of the additional works is 3.9 million euros plus VAT.Nordecon (www.nordecon.com) is a group of construction companies whose core business is construction project management and general contracting in the buildings and infrastructures segment. Geographically the Group operates in Estonia, Sweden, Finland and Ukraine. The parent of the Group is Nordecon AS, a company registered and located in Tallinn, Estonia. The unaudited consolidated revenue of the Group in 2020 was 296 million euros. Currently Nordecon Group employs close to 710 people. Since 18 May 2006 the company’s shares have been quoted in the main list of the NASDAQ Tallinn Stock...

Nordecon AS kontserni ettevõte OÜ Kaurits ja GRK Infra AS sõlmisid töövõtulepingu lisa täiendavate pinnasetööde teostamiseks Tartu maantee Võõbu–Mäo teedeehituse objektil (põhilepingu börsiteade). Täiendavate tööde maksumus on 3,9 miljonit eurot, millele lisandub käibemaks.Nordeconi kontsern (www.nordecon.com) hõlmab ettevõtteid, mis on keskendunud hoonete ja rajatiste ehitamise projektijuhtimisele ja peatöövõtule. Geograafiliselt tegutsevad kontserni ettevõtted Eestis, Rootsis, Soomes ja Ukrainas. Kontserni emaettevõte Nordecon AS on registreeritud ja asub Tallinnas, Eestis. Kontserni 2020. aasta auditeerimata konsolideeritud müügitulu oli 296 miljonit eurot. Nordeconi kontsern annab hetkel tööd ligi 710 inimesele. Alates 18.05.2006 on emaettevõtte aktsiad noteeritud Nasdaq Tallinna Börsi põhinimekirjas.Andri HõbemägiNordecon ASInvestorsuhete...

Vancouver, March 1, 2021 – Leading Edge Materials Corp. (“Leading Edge” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) wishes to announce it has appointed Sanjay Swarup as the new CFO of the Company replacing Nick Demare effective as of today.Mr. Swarup holds a Master of Business Administration from Cranfield School of Management (Bedforshire, UK) and is a chartered accountant from India and the UK with over 25 years of experience in accounting and business consulting, with 15 of those years in the resource industry. Mr. Swarup has held the role of CFO for a number of UK and Canadian listed resource companies. Between 2009 and 2018 Mr. Swarup was the CFO of TSX-listed Mandalay Resources which operates a producing gold mine in Sweden.Filip Kozlowski, CEO states “I am looking forward to working with an experienced...

STOCKHOLM, SWEDEN – March 1, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that Per Aniansson has been appointed as new CFO and Investment Director. He has extensive experience in investments, business development and financing of high-growth companies in the life science industry. Per Aniansson takes up the position on March 7 and will initially work part-time (50%) in the company. He replaces Fredrik Järrsten, who has chosen to move on to a leading position within another life science company.Per Anainsson (b. 1966), Master of Science in Engineering and MBA, has over 20 years of experience from the venture capital industry. He has also been CEO of two MedTech companies and CFO of a wind power company. Per has been responsible for a large number of significant investments, fund raisings and exits, and has participated...

STOCKHOLM, SVERIGE 1 mars 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att Per Aniansson har utsetts till ny finansdirektör och Investment Director. Han har omfattande erfarenhet av investeringsverksamhet, affärsutveckling och finansiering av tillväxtbolag inom life science-industrin. Per Aniansson tillträder positionen den 7 mars och kommer inledningsvis att arbeta deltid (50%) i bolaget. Han ersätter Fredrik Järrsten som valt att gå vidare till en ledande befattning inom ett annat life science-företag.  Per Anainsson (f. 1966), civilingenjör och MBA, har över 20 års erfarenhet från riskkapitalbranschen. Han har även varit vd för två medicintekniska bolag och CFO i ett vindkraftbolag. Per har ansvarat för en lång rad signifikanta investeringar, kapitalanskaffningar och bolagsförsäljningar, och har medverkat...

日本での製造販売に向けて、武田へのCOVID-19ワクチン技術移転にも合意規制承認申請のため、武田が免疫原性および安全性試験で投薬開始メリーランド州ゲイザースバーグ発, March 01, 2021 (GLOBE NEWSWIRE) — 重症感染症の次世代ワクチンを開発するバイオテクノロジー企業ノヴァヴァックス (Novavax, Inc.) (Nasdaq: NVAX) は本日、8月に発表された武田薬品工業 (Takeda Pharmaceutical Company Limited) との協力関係の進展について発表した。両社は独占ライセンス契約を締結しており、武田はノヴァヴァックスのCOVID-19ワクチン候補であるNVX-CoV2373を日本で開発、製造、販売を行う。さらに、武田は第Ⅱ相試験でノヴァヴァックスのワクチン候補の投与を開始し、日本の被験者で免疫原性と安全性を試験していく。ノヴァヴァックス社長兼最高経営責任者のスタンレー･C･エルク (Stanley C. Erck) は次のように述べている。「この契約を通じて、武田とのコラボレーションをさらに進め、このワクチンが日本で導入されるようにしていきます。COVID-19パンデミックを収束するには、NVX-CoV2373などのワクチンが広く行き渡るようにすることが不可欠です。武田はこれを実現するのに最適の立場にあります。」ノヴァヴァックスと武田は、日本でのワクチン製造、臨床開発、規制活動で連携していく。ノヴァヴァックスは武田にワクチン抗原の製造技術を移転し、Matrix-M™アジュバントを供給する。武田では、年間2億5,000万回分以上のCOVID-19ワクチン製造能力を見込んでいる。ノヴァヴァックスは、開発および販売の特定マイルストーンの達成時に支払いを受け取るとともに、ワクチン収益の一部も受け取る権利を保有する。武田は、日本でプラセボ対照盲検化第Ⅰ/Ⅱ相試験をすでに開始しており、20歳以上の200人の健康な被験者を対象に、NVX-CoV2373...